stevenallan / iStockphoto.com
13 March 2018Europe
Pay-for-delay settlements remain steady in EU
The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.
Editor's picks
Editor's picks
Americas
6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.
Americas
6 November 2017 Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.